ClinicalTrials.gov
public full text
Public Domain
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer#429748
- 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer#889336
- Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer#1096152
- Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation#840426
- Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer#1173979
Record · ID 1112119
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive